Form 8-K BIOGEN INC. For: Jan 13

Go back to Form 8-K BIOGEN INC. For: Jan 13

Biogen expects $222M charge from research deals in Q4 2025

January 14, 2026 6:07 AM EST

Biogen Inc. (NASDAQ: BIIB) announced it expects approximately $222 million in pre-tax charges for the fourth quarter of 2025 related to acquired in-process research and development, upfront and milestone expenses.

The biotechnology company said the estimated charge will impact both GAAP and non-GAAP net income... More